Capital Raising Presentation – October 2024

Presentation Highlights:

• Amplia Therapeutics Ltd. (ASX: ATX) is advancing its lead propietary compound, narmafotinib, a best-in-class FAK inhibitor drug in the treatment of pancreatic and other solid tumors, with its ACCENT Phase 2a clinical trial demonstrating highly positive efficacy signals while nearing completion for full enrollment.
  The trial has already achieved its initial activity threshold, and full enrollment of the planned 50 patients is expected soon, with topline results anticipated by Q3 FY25.
• The U.S. FDA has granted narmafotinib for both Orphan Drug and Fast Track designations, positioning Amplia with approvals for 7 years of market exclusivity, tax credits eligibility, and an expedited pathway for regulatory reviews, preparing its market entry for pancreatic cancer treatment.
• To fund its expanding clinical program, Amplia is organizing a capital raise of approximately AUD 13.0M (USD 8.55M) through a combination of a Placement, Director Placement, and Entitlement Offer to support its clinical program. This includes the completion of the ACCENT Phase 2a trial, a new U.S.-based dose-escalation study using FOLFIRINOX for patients with advanced pancreatic cancer, as well as additional preclinical and manufacturing research from future studies.